Investor's Business Daily on MSN
Travere, IBD stock of the day, is on path to $3 billion and in a buy zone
Travere Therapeutics is Thursday's IBD Stock Of The Day. Shares are lingering around a buy zone after gapping up on an FDA ...
Ligand Pharmaceuticals Inc () has held its Q1 earnings call. Read on for the main highlights of the call. Meet Samuel – Your Personal Investing Prophet. Start a conversation wit ...
In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on Erasca, with a price target of $23.00. The company’s shares closed yesterday at $10.46. C ...
In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings expected to grow by 17% per annum in the coming years. In this context, identifying stocks ...
In the last week, the United States market has stayed flat, yet it is up 27% over the past year with earnings forecasted to grow by 17% annually. In such an environment, identifying potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results